Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 4, 2001, Pages 561-568

  Janatuinen, Tuula ^a   Laaksonen, Reijo ^b,c   Vesalainen, Risto ^a   Raitakari, Olli ^a   Lehtimäki, Terho ^b   Nuutila, Pirjo ^a   Knuuti, Juhani ^a,d  

^a UNIVERSITY OF TURKU   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d TURKU PET CENTRE   (Finland)

Author keywords

Blood flow; Hypercholesterolemia; Positron emission tomography; Pravastatin

Indexed keywords

ADENOSINE; ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART MUSCLE BLOOD FLOW; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREMIA; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; CORONARY CIRCULATION; DOUBLE-BLIND METHOD; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; PRAVASTATIN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034837569     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200110000-00008     Document Type: Article

References (30)

1. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults
2. Coronary flow reserve is impaired in young men with familial hypercholesterolemia
3. Coronary flow reserve in young men with familial combined hyperlipidemia
4. Coronary flow reserve is reduced in young men with IDDM
5. Early impairment of coronary flow reserve in young men with borderline hypertension
6. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
7. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
8. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
9. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients
10. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: A potential noninvasive marker of healing coronary endothelium
11. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse
12. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin
13. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy
14. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis
15. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease
16. Current methodology for oxygen-15 production for clinical use
17. Radiochemistry automation for PET
18. Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography
19. 15O and dynamic positron emission tomography: Strategy for quantification in relation to the partial-volume effect
20. Myocardial blood flow: Comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide inhalation
21. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
22. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study
23. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
24. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
25. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men
26. Molecular biology of the renin-angiotensin system
27. Flow-induced release of endothelium-derived relaxing factor
28. Different endothelial mechanisms involved in coronary responses to known vasodilators
29. Endothelium-dependent responses of cerebral arterioles to adenosine 5′-diphosphate
30. Role of nitric oxide and alpha-adrenerglc vasoconstriction in regulation of hyperemic myocardial perfusion